At a meeting with representatives of the Government of the Kirov Region on December 18, Nanolek CEO Evgeny Barinov presented the company’s preliminary results for 2025. Based on year-end projections, Nanolek’s revenue increased by 14% year-on-year and is expected to reach RUB 28.8 billion.

In October 2025, with the participation of the federal Industrial Development Fund (IDF), Nanolek launched Russia’s first domestic full-scale production of a human papillomavirus (HPV) vaccine. The total volume of Nanolek’s investments amounts to RUB 7.5 billion, including RUB 950 million provided by the IDF as a concessional loan under its flagship Development Projects program for the purchase of high-tech equipment.

Chairman of the Government of the Kirov Region Mikhail Sandalov emphasized the importance of the company’s work for the region and the country as a whole.

“The project being implemented by Nanolek in the Kirov Region represents investment in the regional economy and a contribution to strengthening the country’s technological sovereignty. It is important for us that full-cycle manufacturing facilities are being created in the region,” Mikhail Sandalov noted.

The establishment of capacities for the production of a domestic HPV vaccine is being carried out in line with the Strategy for the Development of Immunoprophylaxis of Infectious Diseases in the Russian Federation through 2035. The manufacturing process is organized as a full cycle – from antigen production to the release of the finished product.

“Our HPV vaccine manufacturing initiative includes the construction of two antigen production units. The capacity of the first unit, launched in the Kirov Region, is at least 600,000 vaccine doses per year. By 2027, with the launch of the second unit, total annual capacity will exceed 3 million doses. The expansion of production will create approximately 120 new jobs over the next two years,” Nanolek CEO Evgeny Barinov said at the meeting.

Earlier, in March 2025, Nanolek registered the first Russian vaccine for the prevention of human papillomavirus infection. The vaccine, Сegardex, is the result of work by Russian scientists. The product was developed within a partnership between Nanolek and NPK Combiotech. It underwent the required scope of clinical trials, confirming a high efficacy and safety profile; in March 2025, it received marketing authorization for use in adults. In August, a dossier containing the results of clinical trials involving children was submitted to the Russian Ministry of Health. An extension of indications to this age group is expected in February 2026.

Nanolek representatives proposed developing a comprehensive HPV prevention program in the Kirov Region, including public awareness campaigns on vaccination and educational activities for healthcare professionals.

The meeting also covered the first use of Hunterase® Neuro in Russia. A patient from Astrakhan received treatment for Hunter syndrome with Hunterase® Neuro in November of this year. Thanks to the support provided by the Circle of Kindness Foundation, Russia became the second country in the world after Japan to offer access to this innovative therapy. The product became available in Russia through a partnership between Nanolek and South Korean company GC Biopharma.